CRP Testing Guidelines

Indications for Repeat Testing

For patients with elevated CRP due to acute illness, repeat testing is recommended once the patient has recovered clinically to confirm normalization, as recommended by the American Heart Association 1
If the initial CRP level is ≥10 mg/L, the test should be repeated and the patient examined for ongoing sources of infection or inflammation, according to the American Heart Association 2, 1
In patients with inflammatory conditions who have achieved symptomatic remission, repeat measurement of CRP in 3-6 months is recommended to confirm resolution of inflammation, as suggested by the American Gastroenterological Association 3, 4

Normalization of CRP indicates resolution of the inflammatory process, as indicated by the American Gastroenterological Association 3
Persistently elevated CRP despite clinical improvement warrants further investigation, according to the American Gastroenterological Association 4
For cardiovascular risk assessment, CRP values should be categorized as: Low risk: <1.0 mg/L, Average risk: 1.0-3.0 mg/L, High risk: >3.0 mg/L, as recommended by the American Heart Association 2, 1

In cardiovascular risk assessment, two separate CRP measurements (optimally 2 weeks apart) should be averaged to obtain a stable estimate, as suggested by the American Heart Association 2, 1
In inflammatory bowel disease, if CRP was elevated during an initial flare, normalization suggests endoscopic improvement, according to the American Gastroenterological Association 5, 3
In patients with inflammatory bowel disease, if CRP remains elevated in a patient with symptomatic remission, repeat measurement in 3-6 months is recommended before proceeding to more invasive testing, as recommended by the American Gastroenterological Association 3, 4

CRP normalizes more quickly than ESR during resolution of inflammation, as indicated by the American Heart Association 6
Relying solely on symptoms without confirming normalization of inflammatory markers may miss ongoing subclinical inflammation, according to the American Gastroenterological Association 3
Using ESR instead of CRP to monitor response to treatment after IVIG therapy can be misleading, as IVIG elevates ESR independently of inflammation, as suggested by the American Heart Association 6